| abstract |
The invention relates to compounds of formula (I): wherein: R1 represents a group selected from: each of which optionally contain a further heteroatom N, Z represents an optional substituent halogen, -CH2NH2, -NRaRb or -CN, Z' represents an optional substituent halogen, -CH2NH2, or -CN, alk represents alkylene or alkenylene, T represents S, O or NH; R2 represents hydrogen, -C1-3alkylCONRaRb, -C1-3alkylCO2C1-4alkyl, -C1-3alkylmorpholino, -CO2C1-4alkyl, or -C1-3alkylCO2H; X represents phenyl or a 5 or 6 membered aromatic or non-aromatic heterocyclic group containing at least one heteroatom selected from O, N or S, each of which is optionally substituted by 0-2 groups selected from: halogen, -CN, -C1-4alkyl, -C2-4alkenyl, -CF3, -NRaRb ,-NO2, -N(C1-4alkyl)(CHO), -NHCOC1-4alkyl, -NHSO2Rc, C0-4alkylORd, -C(O)Rc, -C(O)NRaRb, -S(O)nRc, and-S(O)2NRaRb; Y represents (i) a substituent selected from hydrogen, halogen, -CN, -C1-4alkyl, -C2-4alkenyl, -CF3, -NRaRb,-NO2,-N(C1-4alkyl)(CHO), -NHCOC1-4alkyl, -NHSO2Rc, C0-4alkylORd, -C(O)Rc, -C(O)NRaRb,-S(O)nRc, or -S(O)2NRaRb, or (ii) phenyl or a 5 or 6 membered aromatic or non-aromatic heterocyclic group containing at least one heteroatom selected from O, N or S, each of which is optionally substituted by 0-2 groups selected from: halogen, -CN, -C1-4alkyl, -CF3, -(CH2)nNRaRb, -(CH2)nN+RaRbCH2CONH2, C0-4alkylORd, -C(O)Rc, - C(O)NRaRb, -S(O)nRc, -S(O)2NRaRb,=O, oxide to a ring N, -CHO, -NO2, and -N(Ra)(SO2Rc); Ra and Rb independently represent hydrogen, -C1-6alkyl, or together with the N atom to which they are bonded form a 5-, 6- or 7- membered heterocyclic ring optionally containing an additional heteroatom selected from O, N or S, optionally substituted by C1-4alkyl, and optionally the S heteroatom is substituted by O i.e. represents S(O)n; Rc represents -C1-6alkyl; Rd represents hydrogen or -C1-6alkyl; n represents 0-2; and pharmaceutically acceptable derivatives thereof. The invention also relates to processes for the preparation of compounds of formula (I), pharmaceutical compositions containing compounds of formula (I) and to the use of compounds of formula (I) in medicine, particularly in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated. |